Blood Plasma Market, By Product (Immunoglobulins, Albumin, Coagulation Factor Concentrates, Alpha-1 Antitrypsin, and Others), By Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrands Disease, and Others), By Therapeuti

The global blood plasma market has emerged as a vital component of the healthcare industry, playing a crucial role in the treatment of various chronic and life-threatening diseases. Blood plasma, the liquid portion of blood, contains essential proteins, clotting factors, and antibodies that are used in the development of therapeutic products. The market's significance lies in its ability to address the growing demand for plasma-derived therapies, which are used to treat conditions such as immune deficiencies, hemophilia, and neurological disorders. As the prevalence of these diseases continues to rise, coupled with advancements in plasma collection and fractionation technologies, the global blood plasma market is poised for substantial growth.

Market Dynamics:

The global blood plasma market is driven by several factors, including the increasing prevalence of chronic diseases, the growing geriatric population, and the rising demand for immunoglobulins. The expanding applications of plasma-derived therapies in the treatment of various medical conditions, such as primary immunodeficiency disorders and neurological diseases, further fuel the market's growth. Additionally, advancements in plasma collection and fractionation technologies have improved the efficiency and safety of plasma-derived products, thereby boosting market growth. However, the market also faces certain restraints, such as the high cost of plasma-derived therapies and the risk of transmission of blood-borne infections. Moreover, stringent regulations governing the collection, processing, and distribution of blood plasma products can pose challenges to market participants. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing demand for plasma-derived therapies in emerging economies, the development of novel plasma-derived products, and the rising adoption of recombinant plasma proteins. Furthermore, the growing awareness about the benefits of plasma donation and the expansion of plasma collection centers worldwide are expected to contribute to the market's growth in the coming years.

Key Features of the Study:

• This report provides in-depth analysis of the global blood plasma market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global blood plasma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory (BPL), LFB Group, Sanquin Plasma Products, China Biologic Products Holdings, Inc, ADMA Biologics, GC Pharma, CSL Plasma, Emergent BioSolutions, Kamada, and Centurion Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global blood plasma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood plasma market

Market Segmentation

• Product Insights (Revenue, USD Mn, 2020 - 2032)
• Immunoglobulins
• Albumin
• Coagulation Factor Concentrates
• Factor VIII
• Factor IX
• Von Willebrand Factor
• Prothrombin Complex Concentrate
• Fibrinogen Concentrates
• Factor XIII
• Alpha-1 Antitrypsin
• Others
• Application Insights (Revenue, USD Mn, 2020 - 2032)
• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Hemophilia
• Von Willebrand's Disease
• Others
• Therapeutic Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Immunology
• Oncology
• Pulmonology
• Rheumatology
• Transplantation
• Neurology
• Hematology
• Others
• Source Insights (Revenue, USD Mn, 2020 - 2032)
• Source Plasma
• Recovered Plasma
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals & Clinics
• Research Laboratories
• Plasma Collection Centers
• Academic & Research Institutes
• Biopharmaceutical Companies
• Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• CSL Behring
• Grifols
• Takeda Pharmaceutical Company Limited (formerly Shire)
• Octapharma
• Kedrion Biopharma
• Bio Products Laboratory (BPL)
• LFB Group
• Sanquin Plasma Products
• China Biologic Products Holdings, Inc
• ADMA Biologics
• GC Pharma
• CSL Plasma
• Emergent BioSolutions
• Kamada
• Centurion Pharma

Show more